Particles, DNA and RNA
AssigneeNovoscope IP Limited
InventorJasper Clube
Life of this patent
Estimating the term…
Abstract
The invention provides competitive particles, such as virus-like particles, RNAs and DNAs for the treatment or prevention of viral infections and methods of using such particles for treating or preventing or reducing the risk of viral infections (or symptoms thereof) in a subject, such as a human or animal subject. For example, the method herein is a method of reducing or reducing the establishment of a zoonotic population of a virus in an animal, such as a livestock or wild animal (eg, a bat, camelid or a Pholidota (eg, a pangolin)).
Claims25
A method of treating or reducing the risk of an infection or a symptom of an infection in a human or animal subject by a virus, the method comprising:
- administering to the subject a pharmaceutical composition comprising a plurality of a particle comprising a first RNA,
- wherein the particle introduces the first RNA into host cells of the subject for transcription of the first RNA, wherein the first RNA or a transcript thereof comprises a Transcription Regulatory Sequence Core Element (TRS-CE),
- wherein the virus is capable of infecting host cells of the subject, wherein the virus comprises an RNA genome comprising an RNA leader sequence (L) wherein L comprises a first Transcription Regulatory Sequence Core Element (TRS-CE1), wherein replication of the virus comprises the transcription of a first sub-genomic RNA (sgRNA1),
- wherein the sgRNA1 comprises a second Transcription Regulatory Sequence Core Element (TRS-CE2), wherein TRS-CE1 is capable of hybridising to TRS-CE2 in the host cells;
- wherein when the viral RNA is present in a host cell with the first RNA or the transcript, the TRC-CE of the first RNA or transcript hybridizes to the TRS-CE1 or TRS-CE2 comprised by the viral RNA, wherein the hybridising reduces viral replication.
A method of inhibiting replication of a virus in a host cell, wherein the virus comprises a (+)ssRNA genome wherein the viral genome comprises a TRS-L CE and encodes an sgRNA transcript comprising a TRS-B CE (CE2), the method comprising
- a) contacting the host cell with a particle comprising a first RNA,
- wherein the particle introduces the first RNA into the host cell for transcription of the first RNA, wherein the first RNA is a (+)ssRNA that comprises a sequence that is a complement of the CE2;
- b) simultaneously to step (a), subsequent to step (a) or before step (a) the viral RNA genome is introduced into the host cell;
- and
- c) a transcription process is carried out wherein the first RNA is transcribed in the cell to produce an RNA transcript comprising CE2 or a sequence that is capable of hybridising to a viral TRS-L CE, wherein the transcript hybridises to a TRS-L CE comprised by (+)ss RNA of the virus to form an RNA hybrid, and the hybrid is used to produce a mRNA comprising a leader sequence (L), wherein the leader is not operably linked to an RNA sequence that encodes an amino acid sequence (A) of a protein required for replication, propagation or infectivity of said virus.
An engineered RNA, wherein the RNA is a
- (A) (+)ssRNA comprising a complement sequence (CS) of a TRS-B CE of a sgRNA produced by a virus that infects host cells of a human or animal subject, wherein the (+)ssRNA is devoid of one, more or all open-reading frame (ORF) sequences of the virus and is transcribable in a host cell to produce one or more transcripts each comprising a TRS-B CE;
- wherein each TRS-B CE is capable of hybridizing to a TRS-L CE of the virus whereby each transcript is capable of inhibiting the expression of one or more virus ORF protein products;
- or
- (B) (−) ssRNA comprising a complement sequence (CS) of a TRS-L CE of a leader sequence (L) of virus that infects host cells of a human or animal subject, wherein the (−) ssRNA is devoid of one, more or all open-reading frame (ORF) sequences of the virus and is transcribable in a host cell to produce one or more transcripts each comprising a TRS-L CE;
- wherein each TRS-L CE is capable of hybridizing to a TRS-B CE of a sgRNA produced by the virus whereby each transcript is capable of inhibiting the expression of one or more virus ORF protein products.
Dependencies are inferred from the claim text.